Shattuck Labs, Inc. (NASDAQ:STTK) Stock Has Consensus Price Target of $13.70

Key Points

• Analysts maintain a bullish outlook: Shattuck Labs has a consensus “Buy” rating from 13 analysts, with an average 12-month price target of $13.70 versus shares opening at $5.37.
• Stock performance and earnings: STTK recently traded down 0.9%, with a 12-month range of $1.72 to $8.33. The company reported a quarterly loss of $0.12 per share, in line with estimates, and analysts expect a full-year loss of $0.45 per share.
• Institutional ownership is significant: Hedge funds and other institutional investors own 58.74% of the stock, with firms including Frazier Life Sciences Management and Wellington Management recently establishing positions.

Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) has earned a consensus rating of "Buy" from the thirteen analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and three have given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $13.70.

Several research firms recently commented on STTK. HC Wainwright dropped their price target on shares of Shattuck Labs from $18.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, August 11th. UBS Group started coverage on shares of Shattuck Labs in a research note on Sunday, October 11th. They set a "buy" rating and a $17.00 target price on the stock. JPMorgan Chase & Co. started coverage on Shattuck Labs in a research report on Friday, July 24th. They set an "overweight" rating and a $10.00 target price on the stock. Wall Street Zen lowered Shattuck Labs from a "buy" rating to a "hold" rating in a research note on Saturday, August 15th. Finally, Wedbush lifted their price target on Shattuck Labs from $11.00 to $14.00 and gave the company an "outperform" rating in a research note on Friday, October 2nd.

Shattuck Labs Trading Down 0.9%

Shares of NASDAQ:STTK opened at $5.37 on Tuesday. Shattuck Labs has a 12-month low of $1.72 and a 12-month high of $8.33. The business has a 50 day moving average of $6.58 and a two-hundred day moving average of $6.51. The company has a market capitalization of $538.93 million, a PE ratio of -10.53 and a beta of 1.09.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). Equities research analysts predict that Shattuck Labs will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Shattuck Labs

A number of institutional investors and hedge funds have recently made changes to their positions in STTK. Squarepoint Ops LLC lifted its position in shares of Shattuck Labs by 129.6% during the 2nd quarter. Squarepoint Ops LLC now owns 71,547 shares of the company's stock valued at $497,000 after buying an additional 40,385 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Shattuck Labs in the 2nd quarter worth $26,025,000. Wellington Management Group LLP acquired a new position in Shattuck Labs during the second quarter worth $12,269,000. Bank of America Corp DE acquired a new position in Shattuck Labs during the second quarter worth $319,000. Finally, Hsbc Holdings PLC acquired a new position in Shattuck Labs during the second quarter worth $312,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company's research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create biologic medicines that combine immune checkpoint blockade with immune-cell activation in a single therapeutic construct.

Shattuck's pipeline has included investigational ARC fusion proteins intended to alter the tumor microenvironment and stimulate immune responses against cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.